CLEOPATRA set the bar for HER2-positive metastatic breast cancer — but every standard has limits.
Drs. Iyengar, Jhaveri, and Makhlin revisit:
• Why dual HER2 blockade transformed outcomes
• The role of taxanes — and why neuropathy capped treatment
• Where durability and CNS control still fall short
Understanding where we started helps define where we’re going next.
CLEOPATRA Explained: How It Became the First-Line Standard in HER2+ Breast Cancer
You may also like
Recommended Videos
